AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04441229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT mobile application
Description: After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required.
Study NCT00091806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab (ABX-EGF)
Description: 6 mg/kg once every 2 weeks
Study NCT00091806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 9 mg/kg once every 3 weeks
Study NCT04073771 — intervention group
Intervention type: DEVICE
Intervention: Continuous renal replacement therapy with oXiris
Description: Continuous renal replacement therapy with oXiris in patient with septic shock
Study NCT03608176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PASO diet group
Description: This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
Study NCT03608176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet group
Description: This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
Study NCT03608176 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list group
Description: This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
Study NCT02534701 — intervention group
Intervention type: DEVICE
Intervention: ERIC® and SOFIA™
Description: a self-expanding clot retrieval system
Study NCT01075555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Study NCT01075555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Study NCT01075555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT02231554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feldenkrais Method
Description: The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
Study NCT02231554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back School
Description: The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
Study NCT02940509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus Magnesium sulfate
Description: Patients will receive 2 IV infusions:~1. Ketamine (0.5mg/kg)~2. Magnesium sulfate (2g)
Study NCT02940509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
Study NCT04796090 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
Study NCT01148992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: 0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
Study NCT02227680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
Study NCT02227680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage Therapy
Description: Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
Study NCT01148992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg
Study NCT05186142 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography / Ultrasound elastography
Description: Ultrasonography / Ultrasound elastography
Study NCT03537027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
Study NCT02544308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Experimental Arm
Study NCT04348916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
Study NCT02544308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Experimental Arm
Study NCT02544308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No further treatment
Description: Comparator Arm
Study NCT03134352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-3101
Description: A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
Study NCT04348916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study NCT03134352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
Study NCT03134352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
Study NCT04203615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation- sham rTMS
Description: Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
Study NCT04203615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation- real rTMS
Description: Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
Study NCT00686114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.
Study NCT00686114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.
Study NCT00686114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
Study NCT00686114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
Study NCT00686114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
Study NCT00686114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tarceva
Description: 150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
Study NCT04307290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride, or Saline
Description: drug infusion from 10 min before the start of surgery to the end of surgery
Study NCT04307290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride, or Saline
Description: drug infusion from 10 min before the start of surgery to the end of surgery
Study NCT01588795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous renal denervation and TMNS
Description: Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
Study NCT01588795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
Description: Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
Study NCT00686114 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Enlarged field radiotherapy
Study NCT01701570 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Control
Description: The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
Study NCT01701570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training
Description: The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
Study NCT00686114 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional field radiotherapy
Study NCT01182090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
Study NCT01182090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
Study NCT01163227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (single and multiple doses)
Study NCT01959711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior RA
Description: Posterior retroperitoneoscopic adrenalectomy
Study NCT01959711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral transperitoneal LA
Description: Lateral transperitoneal laparoscopic adrenalectomy
Study NCT03926663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa.
Study NCT01163227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051 2 mg (single and multiple doses)
Study NCT01163227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051 15mg (single and multiple doses)
Study NCT01163227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051 100mg (single dose), and 50mg (multiple doses)
Study NCT01462253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine, Cyclophosphamide
Description: The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
Study NCT03926663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
Study NCT03926663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
Study NCT02065258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana
Study NCT02065258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
Study NCT03828019 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (ADA)
Description: Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
Study NCT02185404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing the iStride device
Description: The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 250 mg
Description: Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
Study NCT03828019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional immunosuppression (CON)
Description: The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
Study NCT00882297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echoguided vein puncture
Description: Puncture with echographic visualization of vein in transversal and longitudinal way.
Study NCT02707575 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
Study NCT03703193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
Study NCT03703193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: A single session of modulatory interventions targeting modulation of central nervous system.
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 125 mg
Description: Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 500 mg
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: imipenem/cilastatin 500 mg
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to relebactam
Description: Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
Study NCT01505634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
Study NCT03957564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with PSOX regimen.
Description: Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle.